RORC and neoplasm: To test if RORγ agonists would enhance the tumor killing activity of cytotoxic Tc17 cells, OT-I Tc17 effector cells were generated in the presence or absence of LYC-54143, and then titrated onto CFSE-labeled, ovalbumin-expressing EG7 tumor cells.